Bain Capital Life Sciences Investors, LLC

Bain Capital Life Sciences divests ~2M shares of HTFL across four tranches totaling ~$58.9M in late April.

Bain Capital Life Sciences, a major institutional shareholder owning roughly 10% of HeartFlow, executed a multi-day liquidation of approximately 2 million shares across late April. This is a portfolio management decision by an investment fund, not insider sentiment from operational leadership—Bain holds no officer or director roles. The timing coincides with the stock trading well below its recent highs after a period of volatility, suggesting Bain may have chosen to exit while the stock stabilized around current levels rather than waiting for a recovery. HeartFlow itself remains unprofitable with significant quarterly losses, though revenue is growing at a strong pace, making the company a classic high-growth, pre-profitability biotech. Institutional holders like Bain often harvest gains or rebalance positions based on portfolio targets rather than company-specific concerns, so this sale alone does not signal distress—it's routine fund management of a mature stake.

Bain Capital Life Sciences purchased 1,562,500 shares at $16.00, raising stake to 22,583,268 shares; cluster buy pattern with 4 other insiders in past 14 days

Bain Capital Life Sciences Investors, LLC, a 10% owner, acquired 1,562,500 shares at $16.00 on 2026-04-20, increasing its position to 22,583,268 shares. The purchase occurred at a price 35% below the current market price of $24.61, which is notable given that KLRA has been publicly traded for only 2 trading days. The filing reflects a derivative-conversion transaction, meaning the investor's complete position includes derivative securities not yet fully populated in available data; this purchase represents a specific batch transaction rather than a portfolio-level move. Most significantly, this buy is part of a cluster pattern in which 4 other insiders also purchased shares within the past 14 days, suggesting broad insider confidence in valuation at the early stage of public trading. For a newly listed stock, synchronized insider accumulation across multiple stakeholders warrants close attention to the underlying fundamentals and business trajectory.

Bain Capital Life Sciences Investors sold 2,000,000 shares of Heartflow (HTFL) at $28.05 for $56.1M, reducing stake by 16.1%.

A major institutional investor holding 10% of Heartflow executed a substantial sale of 2,000,000 shares at $28.05 on 2026-02-04, reducing its stake from 12,448,158 to 10,448,158 shares. The sale occurs amid material headwinds: the company generated $46.3M in quarterly revenue but posted a net loss of $-50.9M, and the stock has declined 14.9% over 30 days and 14.8% over 90 days, trading 30.5% below its 52-week high of $39.91. Notably, Bain's cross-ticker track record shows a 25.00% win rate on its 4 prior purchases with -17.1% average 90-day returns, suggesting a pattern of less-effective entry timing; this exit occurs as the stock remains significantly depressed relative to its recent trading range. The disproportionate scale of this reduction—eliminating over one-sixth of the stake in a single transaction—warrants careful scrutiny of capital allocation priorities at this unprofitable, loss-generating business.

Bain Capital Life Sciences bought 1,000,000 shares of SLDB at $4.03 on 2025-02-19, raising stake to 5.03M; cluster buy pattern with 2 other insiders in past 14 days.

Bain Capital Life Sciences, a 10% owner of Solid Biosciences, purchased 1,000,000 shares at $4.03, expanding its holdings by 24.8% and establishing a cluster buy pattern alongside 2 other insiders within a 14-day window. The company is currently unprofitable with net income of -$32.7M in its most recent full fiscal year and zero revenue in the latest quarter, reflecting a pre-commercial or distressed biotech profile. Bain's cross-ticker insider track record shows 3 prior buys with an average 30-day return of +28.0%, though a 90-day win rate of only 50.0% indicates mixed timing outcomes historically. The concurrent buying activity by multiple insiders during a period when the stock trades 60.8% below its 52-week high of $14.75 merits observation of whether this represents conviction in the asset or a liquidity/capital-management event at a distressed valuation.

Bain Capital Life Sciences (10% owner) purchases 300,000 OLMA shares at $5.76; stock down 70.9% from 52-week high, firm unprofitable.

Bain Capital Life Sciences Investors, LLC, a 10% stakeholder in Olema Pharmaceuticals, purchased 300,000 shares at $5.76 on 2025-01-08, increasing holdings by 7.5% to 4,300,000 shares and deploying $1,727,370.00 in capital. The timing occurs after substantial deterioration: the stock is at $4.84 (current price), representing a 70.9% decline from the 52-week high of $16.62 and a 58.4% drop over the past 90 days. The company posted net income of $-34,555,000.00 for its most recent full fiscal year. Across the insider's cross-ticker track record, 2 prior open-market buys averaged a 90-day return of +2.6% with a 50% win rate, providing limited predictive signal for this position. The material investment by a substantial existing shareholder during a period of sharply depressed valuation warrants monitoring for what it may signal about the insider's own confidence in the asset's prospects or strategic position.